je.st
news
Tag: with
UK to double French energy supplies with new cable
2016-06-13 16:17:39| BBC News | Business | UK Edition
A privately funded project has announced it will build a 1.1bn cross-Channel power cable that will double the amount of energy the UK presently receives from France.
Tags: with
double
french
supplies
Succeeding with Successor: the UK presses on with its next-gen submarine programme
2016-06-13 01:00:00| Naval Technology
The UK Ministry of Defence has confirmed a further 642m of funding for the Successor submarine programme, bringing the total spend so far to 3.9bn. With the programmes assessment phase totalling 3.9bn and opposition remaining strong, how feasible
Tags: with
programme
successor
presses
Artificial intelligence: Were like children playing with a bomb
2016-06-12 03:24:00| Climate Ark Climate Change & Global Warming Newsfeed
Guardian: Youll find the Future of Humanity Institute down a medieval backstreet in the centre of Oxford. It is beside St Ebbes church, which has stood on this site since 1005, and above a Pure Gym, which opened in April. The institute, a research faculty of Oxford University, was established a decade ago to ask the very biggest questions on our behalf. Notably: what exactly are the existential risks that threaten the future of our species; how do we measure them; and what can we do to prevent them? Or...
Tags: with
children
playing
intelligence
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
2016-06-11 17:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
India finds place in the sun after energy ties with US
2016-06-11 13:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Indian Express: One of the key takeaways of Prime Minister Narendra Modis recent US visit was a strong message about Indias commitment to play a positive catalyst in the global initiative to address the menace of climate change. In his address to the US Congress, Modi made it clear that last years Paris climate deal that India helped broker with the Barack Obama administration was one of the cornerstones of India-US relationship. The address came a day after Modis seventh meeting with Obama. The two have...
Sites : [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] next »